Literature DB >> 31875525

TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.

Hanning Ying1, Lin Ji1, Zhiyao Xu2, Xiaoxiao Fan1, Yifan Tong1, Hui Liu3, Jia Zhao3, Xiujun Cai4.   

Abstract

Tripartite motif 59 (TRIM59) is a member of Tripartite motif protein family, which is frequently increased in many human cancers. However, the molecular mechanism of TRIM59 in hepatocellular carcinoma (HCC) has not been fully elucidated. In this study, we report that TRIM59 plays an essential role in growth of HCC. We analyzed RNA sequencing data to explore abnormally expressed TRIM59 in HCC. The effects of TRIM59 on HCC were investigated through in vitro and in vivo assays (i.e., CCK-8 assay, colony formation assay, flow cytometry assay, xenograft model, immunohistochemistry, immunofluorescence and western blot). The mechanism of TRIM59 action was explored through co-immunoprecipitation, immunofluorescence, mass spectrometry and bioinformatics. TRIM59 expression is up-regulated in HCC tissues. A high level of TRIM59 expression is correlated with poor overall and disease-free survival of HCC patients. Knockdown of TRIM59 attenuated proliferation, induced cells arrested at G1/S phase and reduced tumor growth in the mouse xenograft model. Ectopic expression of TRIM59 had the opposite results. Mechanistically, TRIM59 promoted growth and regulated cell cycle. Further studies indicated that TRIM59 might interacted physically with PPM1B, which has been reported to negatively regulate CDKs phosphorylation. We also discovered that TRIM59 increased degradation of PPM1B. TRIM59 overexpression in HCC patients correlated with reduced expression of PPM1B and increased CDKs phosphorylation and cell cycle proteins. Our findings demonstrate that TRIM59 promotes growth by PPM1B/CDKs signaling pathway, indicating a new prognostic biomarker candidate and a potential antitumor target for HCC.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell cycle; Hepatocellular carcinoma (HCC); PPM1B; TRIM59; Tumor growth

Mesh:

Substances:

Year:  2019        PMID: 31875525     DOI: 10.1016/j.canlet.2019.12.030

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  TRIM59 promotes osteosarcoma progression via activation of STAT3.

Authors:  Guoxing Xu; Zhenjiang Ma; Fei Yang; Yanqiang Bai; Jian Li; Wanglin Luo; Jiangbo Zhong
Journal:  Hum Cell       Date:  2021-10-09       Impact factor: 4.174

2.  Identification of a Functional ceRNA Network to Explore Potential Biomarkers for Hepatocellular Carcinoma.

Authors:  Zhijun Jiang; Yu Zhang; Xinyu Liu; Jingchen Liang; Guanhua Qiu; Xiaoqi Zhu; Jie Chen; Lequn Li
Journal:  Onco Targets Ther       Date:  2020-12-01       Impact factor: 4.147

3.  Identification Prognostic Value and Correlation with Tumor-Infiltrating Immune Cells of Tripartite-Motif Family Genes in Hepatocellular Carcinoma.

Authors:  Hao Su; Yueheng Tang; Kexin Nie; Zhi Wang; Hongzhan Wang; Hui Dong; Gang Chen
Journal:  Int J Gen Med       Date:  2022-02-09

4.  Comprehensive profiling of the TRIpartite motif family to identify pivot genes in hepatocellular carcinoma.

Authors:  Lingyun Wu; Xin Yin; Kan Jiang; Jie Yin; Hao Yu; Lingling Yang; Chiyuan Ma; Senxiang Yan
Journal:  Cancer Med       Date:  2022-02-09       Impact factor: 4.452

Review 5.  TRIM proteins in hepatocellular carcinoma.

Authors:  Kan Lu; Yonglong Pan; Zhao Huang; Huifang Liang; Ze-Yang Ding; Bixiang Zhang
Journal:  J Biomed Sci       Date:  2022-09-13       Impact factor: 12.771

6.  Cancer-derived exosomal TRIM59 regulates macrophage NLRP3 inflammasome activation to promote lung cancer progression.

Authors:  Manman Liang; Xingwu Chen; Lijing Wang; Lilong Qin; Hanli Wang; Zhengui Sun; Wenying Zhao; Biao Geng
Journal:  J Exp Clin Cancer Res       Date:  2020-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.